Use of non-anthracycline adjuvant chemotherapy in triple-negative breast cancer: Review from a prospective registry.

e12071 Background: Adjuvant chemotherapy is recommended for most patients with stage I-III triple negative breast cancer (TNBC). Anthracycline (A) and Taxane (T) form the backbone of most adjuvant regimens. One randomized study has demonstrated that 4 cycles of Docetaxel/Cyclophosphamide (TC) is superior to 4 cycles of non-dose dense AC. In an unselected population of TNBC, the proportion of patients receiving A based versus other adjuvant chemotherapy regimens is not known. Utilizing a prospective registry, our aim was to study the patterns of adjuvant chemotherapy regimens prescribed for TNBC. Methods: 316 stage I-III TNBC patients enrolled in a multisite IRB approved registry between 2011 and 2014. Patients were accrued at academic and community oncology clinics. Clinical, demographic and chemotherapy information was collected. This study was restricted to analysis of 146 study participants who received adjuvant chemotherapy. Results: For the 146 subjects, median age was 55 years (range 27-84), 17%: Af...